Clinical trial
A Randomized, Double-blinded, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine
NCT05602558 is registered in ClinicalTrials.gov with Yantai Patronus Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blinded, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine
- Lead sponsor
- Yantai Patronus Biotech Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- December 31, 2022
- Completion date
- February 29, 2024
- Enrollment
- 18,000 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.